Uterine cavity treatment device

Abstract

The invention provides a uterine cavity treatment device, and belongs to the technical field of uterine cavity postoperative continuous treatment devices. The treatment device comprises a uterine cavity support and a conveying system, the uterine cavity support comprises a supporting framework and a medicine carrying covering film, a main body of the supporting framework is of a big-end-up three-dimensional cage-shaped structure, angle-shaped protrusions are symmetrically arranged on the left side and the right side of the far end of the supporting framework, and the angle-shaped protrusions obliquely extend upwards with the center of the uterine cavity support as the reference; an arc-shaped structure is formed, so that the whole shape of the supporting skeleton is matched with the uterus shape after the supporting skeleton is automatically expanded; the medicine carrying covering film is at least arranged on the outer side of the supporting framework; a hormone sustained-release drug is arranged in the drug-loading covering membrane and is used for promoting repair of endometrium; the conveying system is used for loading the uterine cavity stent in a contracted state and conveying the uterine cavity stent to a target position to complete release; the technical problem that in the prior art, the effect of treating intrauterine adhesion after an intrauterine operation is poor is mainly solved.

Description

Technical Field

[0001] This invention belongs to the technical field of postoperative treatment devices for uterine cavity, and specifically relates to a uterine cavity treatment device. Background Technology

[0002] Intrauterine adhesions are a common gynecological condition caused by damage to the endometrium, leading to partial or complete blockage of the uterine cavity. While numerous methods exist to prevent recurrence after adhesiolysis, a completely effective method to prevent recurrence remains elusive, and there is a lack of standardized treatment guidelines. Current treatment methods primarily include medication, intrauterine device (IUD) blocking, thin-film anti-adhesion products, and balloon dilation.

[0003] The main medication used in drug treatment is estrogen. After adhesiolysis, sequential artificial cycle therapy with estrogen and progesterone is routinely used for 2-3 months, or estrogen alone. This is effective in preventing re-adhesion after adhesiolysis in patients with mild to moderate intrauterine adhesions, and can significantly improve menstrual recovery and reproductive prognosis. However, the systemic bioavailability of oral estradiol is low; usually only 2% to 10% of the drug enters the systemic circulation. This is because oral estradiol undergoes its first metabolism in the gastrointestinal tract and liver, resulting in most of the drug being metabolized before entering the systemic circulation. Furthermore, long-term use of estradiol may increase the risk of endometrial hyperplasia and endometrial cancer.

[0004] Intrauterine device (IUD) blocking involves inserting an IUD into the uterus to separate the uterine wall from the adhesions, preventing the uterine walls from easily adhering together. Currently, most researchers consider placing an IUD in the uterine cavity for 2-3 months after adhesiolysis as a classic method to prevent re-adhesion. However, its effectiveness in preventing re-adhesion in patients with severe intrauterine adhesions is poor, with no significant improvement in postoperative menstrual recovery or reproductive prognosis. Furthermore, the limited area of ​​the IUD prevents effective separation of the anterior and posterior uterine walls and may cause excessive inflammatory reactions. Intrauterine adhesions often occur in the central and horn areas of the uterus. "O"-shaped IUDs are less effective at preventing adhesions in the horns and apex of the uterus. While "T"-shaped IUDs can reach the horns, their separation effect in the central uterus is limited, and the IUD cannot completely cover the uterine cavity, posing a risk of displacement after insertion, resulting in poor treatment outcomes.

[0005] There are also thin-film anti-adhesion products on the market. These products are generally inverted triangular in shape and do not have a three-dimensional structure. The disadvantages of thin-film anti-adhesion products are that they are prone to displacement within the uterine cavity and cannot completely conform to the uterine cavity, posing a risk of local adhesion. In addition, these products are difficult to deliver, requiring a delivery system with a large outer diameter, and can only be implanted after cervical dilation.

[0006] Following uterine surgery, balloon placement is sometimes used to prevent adhesions, but the results are often unsatisfactory. This is because the uterine cavity is pear-shaped or nearly triangular, and the balloon's shape is inconsistent with this shape, failing to completely cover the new uterine cavity wound and prevent the formation of new adhesions. Furthermore, the balloon's uniform shape, similar to an IUD, does not completely cover the uterine cavity, limiting its effect to the central area of ​​the anterior and posterior walls. It offers no protection for other areas such as the uterine horns and uterine apex. Additionally, when inflated, the balloon exerts excessive local pressure on the anterior and posterior walls of the uterus, inhibiting endometrial growth in those areas.

[0007] Therefore, there is a need to provide an improved technical solution that addresses the shortcomings of the existing technology. Summary of the Invention

[0008] The purpose of this invention is to provide a uterine cavity treatment device to solve the technical problem of poor postoperative treatment effect of uterine cavity adhesions in the prior art.

[0009] To achieve the above objectives, the intrauterine treatment device of the present invention provides the following technical solution: A uterine cavity treatment device includes a uterine cavity stent and a delivery system. The uterine cavity stent includes a support frame and a drug-loaded membrane. The main body of the support frame is a three-dimensional cage-like structure that is larger at the top and smaller at the bottom. Angular protrusions are symmetrically arranged on the left and right sides of the distal end of the support frame. The angular protrusions extend upwards at an angle with the center of the uterine cavity stent as a reference, forming an arc-shaped structure. This allows the overall shape of the support frame to adapt to the shape of the uterus after it automatically expands. The drug-loaded membrane is arranged at least on the outside of the supporting skeleton; the drug-loaded membrane contains a sustained-release hormone drug to promote the repair of the endometrium. The delivery system is used to load the intrauterine stent in the contracted state and to deliver the intrauterine stent to the target location for release.

[0010] As a further optimized technical solution, the proximal end of the intrauterine stent is provided with a withdrawal component for removing the intrauterine stent from the treatment site.

[0011] As a further optimized technical solution, the withdrawal component is a tail wire, the distal end of which is fixedly connected to the uterine cavity stent, and the proximal end extends away from the uterine cavity stent.

[0012] As a further optimized technical solution, the support skeleton is woven from braided wires, and the material of the braided wires is nickel-titanium alloy wire with shape memory effect or biodegradable polymer wire.

[0013] As a further optimized technical solution, the drug-loaded coating is integrally formed with the supporting skeleton, and the drug-loaded coating completely covers the supporting skeleton.

[0014] As a further optimized technical solution, the drug-loaded coating is made of silicone, and the thickness of the drug-loaded coating is 0.5-2 times the diameter of the braided filaments.

[0015] As a further optimized technical solution, the supporting skeleton is a cut-out scaffold structure, and the drug-loaded coating covers the outer surface of the supporting skeleton.

[0016] As a further optimized technical solution, the overall thickness of the uterine cavity stent gradually decreases from the middle to the left and right sides when it is inflated.

[0017] As a further optimized technical solution, the delivery system includes a sleeve for receiving the intrauterine stent, and a push rod is slidably disposed inside the sleeve. During operation, the intrauterine stent is received at the distal end of the sleeve in a contracted state. After the sleeve delivers the intrauterine stent into the uterine cavity, the push rod is operated to push the intrauterine stent out of the sleeve, and the intrauterine stent automatically expands to support the uterine cavity.

[0018] As a further optimized technical solution, a positioning sleeve is movably provided on the sleeve to ensure that the intrauterine stent is released in the accurate position within the uterine cavity.

[0019] The beneficial effects are as follows: First, compared with existing balloons and IUDs, the intrauterine stent of this invention, by setting a main body in the shape of an inverted triangle and symmetrically arranged angular protrusions on the left and right sides, makes the intrauterine stent, after expansion, resemble the shape of the uterus. The shape is more in line with the shape of the uterus itself, with a wide coverage area, which can effectively protect the uterine horns, uterine apex and other parts. It solves the problem of insufficient coverage of the uterine horns and uterine apex by traditional IUDs and balloons, achieves comprehensive physical isolation of the intrauterine wound, and greatly reduces the risk of re-adhesion.

[0020] Secondly, the uterine stent of the present invention is adapted to the shape of the uterus itself, so that the supporting force is appropriate and less than the pressure of the balloon and the contraceptive ring on the uterine wall. It can play a certain role in compression and hemostasis without affecting the growth of the endometrium.

[0021] Furthermore, the drug-loaded coating of the present invention contains a sustained-release estrogen drug that can act directly on the uterine cavity to promote endometrial growth, avoiding the metabolic loss of oral drugs and improving drug utilization; at the same time, it reduces the side effects of systemic administration, such as endometrial hyperplasia and carcinogenesis.

[0022] Finally, the intrauterine stent has self-expanding properties, which can improve the adaptability of the intrauterine stent and thus match a larger range of intrauterine cavity sizes. Attached Figure Description

[0023] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. Wherein: Figure 1 This is a schematic diagram of the overall structure of one embodiment of the intrauterine treatment device of the present invention; Figure 2 This is a schematic diagram of the supporting skeleton structure of one embodiment of the intrauterine treatment device of the present invention; Figure 3 This is a front view schematic diagram of a uterine stent according to an embodiment of the uterine cavity treatment device of the present invention; Figure 4 for Figure 3 A left-view diagram; Figure 5 for Figure 3 A top-down view; Figure 6 This is a cross-sectional schematic diagram of the proximal portion of the uterine stent in one embodiment of the uterine cavity treatment device of the present invention; Figure 7 A schematic diagram of the uterine stent release state according to an embodiment of the uterine cavity treatment device of the present invention; Figure 8 A first schematic diagram illustrating the release process of an embodiment of the intrauterine treatment device of the present invention; Figure 9 A second schematic diagram illustrating the release process of an embodiment of the intrauterine treatment device of the present invention; Figure 10 A third schematic diagram illustrating the release process of an embodiment of the intrauterine treatment device of the present invention; Figure 11 A schematic diagram of the supporting skeleton structure of another embodiment of the intrauterine treatment device of the present invention.

[0024] In the diagram: 100, uterine stent; 110, support frame; 120, drug-loaded coating; 130, angular protrusion; 140, withdrawal component; 150, proximal constriction ring; 160, distal constriction ring; 200, delivery system; 210, sleeve; 220, push rod; 230, positioning sleeve; 240, first operating handle; 250, second operating handle. Detailed Implementation

[0025] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention are within the scope of protection of the present invention.

[0026] In the description of this invention, the terms "longitudinal," "lateral," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," and "bottom," etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are used only for the convenience of describing the invention and do not require the invention to be constructed and operated in a specific orientation; therefore, they should not be construed as limitations on the invention. The terms "connected" and "linked" used in this invention should be interpreted broadly. For example, they can refer to a fixed connection or a detachable connection; they can refer to a direct connection or an indirect connection through intermediate components. Those skilled in the art can understand the specific meaning of the above terms according to the specific circumstances. Furthermore, the term "proximal end" uniformly refers to the end closer to the operator, while "distal end" refers to the end farther from the operator.

[0027] The present invention will now be described in detail with reference to the accompanying drawings and embodiments. It should be noted that, unless otherwise specified, the embodiments and features described herein can be combined with each other.

[0028] The shapes and sizes of the components in the accompanying drawings do not reflect the actual proportions of the product; they are only intended to illustrate the content of the invention.

[0029] This invention provides a uterine cavity treatment device, comprising a uterine cavity support 100 and a delivery system 200. The supporting frame 110 of the uterine cavity support 100 has a cage-like structure, with its main body roughly inverted triangular in shape. Angular protrusions 130 are symmetrically arranged on the left and right sides of the distal end of the supporting frame 110, allowing its overall shape to adapt to the uterine morphology after automatic expansion. A drug-loaded membrane 120 is provided on the outer side of the supporting frame 110, containing a sustained-release drug to promote endometrial repair. The delivery system 200 is used to receive the contracted uterine cavity support 100 and to deliver it to the target location (uterine cavity) for release. This invention achieves comprehensive coverage and isolation of the uterine cavity wound through a shape-adapted supporting frame. Combined with the sustained-release effect of the drug-loaded membrane, it effectively solves the technical problems of insufficient coverage of areas such as the uterine horn, low drug utilization, and easy occurrence of side effects in existing technologies such as IUDs and balloons. It can significantly reduce the risk of re-adhesion after uterine adhesion separation and improve the treatment effect.

[0030] Example 1 like Figure 1 As shown, the intrauterine treatment device includes an intrauterine stent 100 and a delivery system 200.

[0031] like Figure 2 , Figure 3 , Figure 4 and Figure 5As shown, the intrauterine support 100 includes a support frame 110 and a drug-loaded coating 120. The main body of the support frame 110 is woven from 12-144 ultra-elastic nickel-titanium alloy wires with a diameter of 0.02mm-0.3mm. After heat treatment, it is shaped into a three-dimensional cage structure that is larger at the top and smaller at the bottom. Its main body is roughly inverted triangular in shape (inverted triangular shape: the base is horizontally arranged at the top, and the two sides are symmetrically arranged on the left and right sides). It should be noted that in this invention, the reason why the main body of the support frame 110 is described as "roughly" inverted triangular in shape is that the shape of the main body of the support frame 110 is not strictly a triangle with every side being a straight line. Instead, each side is designed to be curved to fit the shape of the uterine cavity, so that the support frame 110 fits the uterine cavity more closely. The support frame 110 has symmetrical angular protrusions 130 on the left and right sides at its distal end. The angular protrusions extend upward at an angle with the center of the uterine support 100 as the reference, forming an arc-shaped structure. The width of the angular protrusions 130 gradually narrows from the end closer to the main body of the support frame 110 to the end farther away from the support frame 110, thus forming two protruding angular structures at the distal end of the support frame 110, so that the two sides of the distal end of the uterine support 100 can fully fit the uterine horn.

[0032] The 100-type intrauterine stent, when fully expanded, has a waist dimension (mid-section transverse dimension) of 10mm-40mm and an overall thickness of 2mm-20mm. The thickness is designed to be greatest in the middle and gradually decrease towards the left and right sides (see details...). Figure 5 As shown); the overall height is 20mm-40mm. From the far end to the near end, the width ( Figure 3 The dimensions (in the transverse direction) gradually decrease, with the width at the most distal angled protrusion (130°) being 30mm-50mm, and the width at the closest constricting ring being 5mm-10mm, forming an inverted triangular structure. The proximal end of the support frame 110 is secured by a proximal constricting ring 150 made of nickel-titanium tubing. The proximal constricting ring 150 is laser-beveled to reduce stimulation to the patient. The distal end is secured by a distal constricting ring 160 and, after heat treatment, is embedded within the uterine cavity stent 100. After automatic expansion, the overall shape of the support frame 110 conforms to the shape of the uterus, thus facilitating and fully fitting and supporting the uterine cavity.

[0033] To facilitate the removal of the intrauterine stent 100 after treatment, a removal component 140 is provided at the proximal end of the intrauterine stent 100 for removing the intrauterine stent 100 from the treatment site (uterine cavity). In this embodiment, the removal component 140 consists of two parallel tail wires, with the distal end of the tail wires fixedly connected to the intrauterine stent 100 and the proximal end extending away from the intrauterine stent 100.

[0034] like Figure 6As shown, the drug-loaded membrane 120 is integrally formed with the supporting skeleton 110, and the drug-loaded membrane 120 completely covers the supporting skeleton 110. That is, the drug-loaded membrane 120 is simultaneously arranged on the inner and outer sides of the supporting skeleton 110 and inside the gaps between the nickel-titanium alloy wires. The drug-loaded membrane 120 contains a sustained-release hormone drug to promote endometrial repair. The purpose of this design is: firstly, the design of completely covering the drug-loaded membrane 120 allows the sustained-release hormone drug (such as any one or more combinations of 17β-estradiol, ethinylestradiol, estradiol valerate, and estradiol benzoate) to be released simultaneously from around the supporting skeleton 110 into the uterine cavity, resulting in a wider drug diffusion range, ensuring drug concentration, and thus more comprehensively promoting endometrial repair.

[0035] Furthermore, the integrated molding process combined with the fully encapsulated structure allows the drug-loaded membrane 120 and the supporting skeleton 110 to form a tight, integrated structure, thereby reducing gaps between the drug-loaded membrane 120 and the supporting skeleton 110. This design can effectively resist the effects of intrauterine fluid flushing and stent self-expansion deformation, reducing the risk of cracking and peeling of the drug-loaded membrane 120, and preventing premature drug leakage due to damage to the drug-loaded membrane 120 (even if there is drug leakage in the part of the drug-loaded membrane 120 located on the outer layer of the supporting skeleton 110, the inner part still ensures the therapeutic effect), ensuring the stability of the sustained-release cycle.

[0036] Furthermore, the fully encapsulated structure fills the gaps in the mesh formed by the support skeleton 110 and minor imperfections on the surface of the wires, making the surface of the intrauterine stent 100 smoother and more rounded. This not only reduces mechanical friction damage between the intrauterine stent 100 and the endometrium, but also reduces the risk of inflammatory reactions caused by direct contact between the wires and tissues, thereby improving patient comfort and biocompatibility after implantation.

[0037] In summary, the integrated design of the drug-loaded membrane 120 and the supporting skeleton 110 achieves a synergistic effect of "physical isolation + drug repair" by improving the comprehensiveness of drug release, structural stability and biocompatibility, and further reduces the risk of recurrence of intrauterine adhesions.

[0038] In this embodiment, the drug-loaded membrane 120 is made of silicone material (such as polyvinylidene fluoride, polyurethane, etc.). The silicone membrane contains a sustained-release drug, which is estradiol sustained-release. In this way, the drug-loaded membrane 120 in the uterine cavity releases estradiol, allowing the patient to promote endometrial growth without taking estradiol orally. This avoids the problems of patients being unable to take estradiol orally due to drug contraindications and the side effects of oral estradiol. In addition, it avoids the metabolic loss of oral drugs and improves drug utilization. At the same time, it reduces the side effects of systemic administration, such as endometrial hyperplasia and cancer.

[0039] Furthermore, the thickness of the drug-loaded coating 120 located on one side of the supporting framework 110 is 0.5-2 times the diameter of the nickel-titanium alloy wire. This 0.5-2 times wire diameter range ensures that a sufficient dose of sustained-release drug, such as estradiol, is uniformly mixed within the coating. If the coating is too thin (less than 0.5 times the wire diameter), the drug loading will be insufficient, making it difficult to maintain the long-term drug release required for intrauterine repair, which typically takes 2-3 months. If it is too thick (greater than 2 times the wire diameter), it may lead to an excessive initial drug release, increasing the risk of local adverse reactions, and may also affect the sustained-release stability due to uneven coating degradation.

[0040] In addition, the nickel-titanium alloy wire, serving as the supporting framework 110, needs to maintain the uterine-like shape of the stent through its own strength. If the thickness of the drug-loaded membrane 120 exceeds twice the wire diameter, it will significantly increase the overall rigidity of the intrauterine stent 100, which may make it difficult for the intrauterine stent 100 to conform to the changes in the shape of the uterine cavity during self-expansion, or even cause excessive mechanical stimulation to the uterine cavity wall. When the thickness is not less than 0.5 times the wire diameter, it can ensure that the drug-loaded membrane 120 effectively covers the supporting framework 110, while avoiding the intrauterine stent 100 being too flexible due to the drug-loaded membrane 120 being too thin, thus failing to provide sufficient physical isolation support, such as the inability to effectively separate the anterior and posterior walls of the uterus.

[0041] Furthermore, matching the thickness of the drug-loaded coating 120 to the wire diameter of the supporting skeleton 110 enhances the adhesion between the drug-loaded coating 120 and the nickel-titanium alloy wire. If the coating is too thin, it is prone to cracking and peeling due to minor deformations during the weaving process of the supporting skeleton 110 or the intrauterine environment (such as corrosive bodily fluids), leading to premature drug leakage. If the thickness is moderate (0.5-2 times), a continuous and complete coating layer can be formed, deforming synchronously with the expansion / contraction of the supporting skeleton 110, ensuring the continuity and stability of drug release.

[0042] Furthermore, the mesh size of the distal portion of the intrauterine stent 100 is larger, decreasing towards the proximal portion. This design allows for a relatively spacious and complex uterine cavity in the distal region (near the fundus and horns). The larger mesh size provides better flexibility and deformation capability, adapting to the curvature of the horns and the irregular shape of the fundus, ensuring a tight fit and effective coverage of these easily adhered areas. Conversely, the uterine cavity gradually narrows towards the proximal portion (near the cervix). The reduced mesh size enhances the structural stability of the proximal portion of the intrauterine stent 100, preventing displacement or deformation due to compression in the narrower areas of the uterine cavity, thus ensuring the overall support effectiveness of the intrauterine stent 100.

[0043] like Figure 1 , Figure 7 As shown, the delivery system 200 is used to receive the intrauterine stent 100 in the contracted state and to deliver the intrauterine stent 100 to the target position to complete the release.

[0044] Specifically, in this embodiment, the delivery system 200 includes a sleeve 210, a push rod 220, and a positioning sleeve 230. The sleeve 210 is used to receive the uterine support 100 in its contracted state. The push rod 220 is slidably disposed within the sleeve 210, with its distal end abutting against the proximal end of the uterine support 100. The positioning sleeve 230 is movably fitted onto the sleeve 210, and its positioning can be adjusted by sliding on the sleeve 210 according to the depth of the uterus, thereby ensuring the accurate release of the uterine support 100 within the uterine cavity. A first operating handle 240 is provided at the proximal end of the sleeve 210, and a second operating handle 250 is provided at the proximal end of the push rod 220, thereby facilitating the operator's grip and operation. In this embodiment, the inner diameter of the sleeve 210 is 3mm-6mm, and its length is 150mm-300mm. The inner diameter of the push rod 220 is 0.5mm-2mm smaller than the inner diameter of the sleeve, and its length is 10mm-50mm longer than the length of the sleeve 210. In use, first determine the size and depth of the uterine cavity according to hysteroscopy / ultrasound, and select the appropriate uterine stent 100 model. Then, compress and store the uterine stent 100 at the distal end of the sleeve 210. At this time, the angular protrusion 130 is located at the end away from the first operating handle 240 to ensure that the orientation of the angular protrusion 130 is consistent with the direction of the uterine horn.

[0045] Adjust the position of the positioning sleeve 230 according to the depth of the uterine cavity, and insert the distal end of the sleeve 210 into the uterine cavity until it reaches the bottom of the cavity. At this time, the entire intrauterine support 100 is located at the distal end inside the sleeve 210. Figure 8 As shown.

[0046] Keeping the second operating handle 250 stationary, retract the sleeve 210 towards the operator using the first operating handle 240. The uterine stent 100 gradually releases the restraint of the sleeve 210 and automatically expands within the uterine cavity, as... Figure 9 As shown, when the intrauterine stent 100 finally unfolds into a structure adapted to the shape of the uterus, the drug-loaded membrane 120 contacts the uterine cavity wall and begins to release the drug. Then, the delivery system 200 is withdrawn, and the tail string is cut 3-4 cm from the cervix, completing the implantation of the intrauterine stent 100. Figure 10 As shown. After a certain treatment cycle, the intrauterine stent 100 is removed from the uterine cavity using the tail string.

[0047] Example 2 like Figure 11 As shown, this embodiment provides a support skeleton 110 with a different structure. Unlike embodiment 1, in this embodiment, the support skeleton 110 is a support structure made by laser cutting of nickel-titanium tubes. The support structure is heat-treated to be shaped into a three-dimensional structure consistent with the shape of the uterus. The drug-loaded coating 120 only covers the outer surface of the support skeleton 110.

[0048] Example 3 This embodiment provides a support skeleton 110 made of a different material. Unlike embodiment 1, in this embodiment, the support skeleton 110 is woven from medical polymer materials (such as polylactic acid PLA, polydioxane PDO, L-polylactic acid PLLA, lactide-glycolic acid copolymer PGLA, polyglycolic acid PGA, polycaprolactone PCL, etc.) and the surface is covered with a medicated silicone film. It is suitable for patients who are allergic to metal or who need long-term promotion of endometrial repair.

[0049] In summary, the intrauterine treatment device of the present invention, through its shape-adapted intrauterine stent for support, local drug delivery, and precise delivery system, effectively solves the shortcomings of the prior art, significantly reduces the risk of postoperative intrauterine adhesions, and has high clinical application value.

[0050] It is understood that the above description is merely exemplary and the embodiments of this application do not limit the scope of the application.

[0051] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention are within the protection scope of the present invention.

Claims

1. A uterine cavity treatment device, characterized in that, The device includes an intrauterine stent (100) and a delivery system (200). The intrauterine stent (100) includes a support frame (110) and a drug-loaded membrane (120). The main body of the support frame (110) is a three-dimensional cage-like structure that is larger at the top and smaller at the bottom. Angular protrusions (130) are symmetrically arranged on the left and right sides of the distal end of the support frame (110). The angular protrusions (130) extend upwards at an angle with respect to the center of the intrauterine stent (100) to form an arc-shaped structure, so that the overall shape of the support frame (110) after automatic expansion is adapted to the shape of the uterus. The drug-loaded membrane (120) is arranged at least on the outside of the supporting skeleton (110); the drug-loaded membrane (120) contains a hormone-based sustained-release drug to promote the repair of the endometrium. The delivery system (200) is used to load the intrauterine stent (100) in a contracted state and to deliver the intrauterine stent (100) to the target location to complete the release.

2. The intrauterine treatment device according to claim 1, characterized in that, The intrauterine stent (100) is provided with a withdrawal component (140) at its proximal end for withdrawing the intrauterine stent (100) from the treatment site.

3. The intrauterine treatment device according to claim 1, characterized in that, The withdrawal component (140) is a tail wire, the distal end of which is fixedly connected to the uterine cavity support (100), and the proximal end extends away from the uterine cavity support (100).

4. The intrauterine treatment device according to any one of claims 1-3, characterized in that, The supporting skeleton (110) is woven from braided wires, which are made of nickel-titanium alloy wires with shape memory effect or biodegradable polymer wires.

5. The intrauterine treatment device according to claim 4, characterized in that, The drug-loaded coating (120) is integrally formed with the support skeleton (110), and the drug-loaded coating (120) completely covers the support skeleton (110).

6. The intrauterine treatment device according to claim 1, characterized in that, The drug-loaded coating (120) is made of silicone, and the thickness of the drug-loaded coating (120) is 0.5-2 times the diameter of the braided filaments.

7. The intrauterine treatment device according to any one of claims 1-3, characterized in that, The support frame (110) is a cut-out support structure, and the drug-loaded coating (120) covers the outer contour surface of the support frame (110).

8. The intrauterine treatment device according to claim 1, characterized in that, The overall thickness of the uterine stent (100) gradually decreases from the center to the left and right sides when it is inflated.

9. The intrauterine treatment device according to any one of claims 1-3, characterized in that, The delivery system (200) includes a sleeve (210) for receiving the intrauterine stent (100), and a push rod (220) is slidably disposed inside the sleeve (210). During operation, the intrauterine stent (100) is stored at the distal end of the sleeve (210) in a contracted state. After the sleeve (210) delivers the intrauterine stent (100) into the uterine cavity, the push rod (220) is operated to push the intrauterine stent (100) out of the sleeve (210). The intrauterine stent (100) automatically expands to support the uterine cavity.

10. The intrauterine treatment device according to claim 9, characterized in that, A positioning sleeve (230) is movably provided on the sleeve (210) to ensure that the intrauterine stent (100) is released in the accurate position within the uterine cavity.

Images